Esperion reports Q4 EPS 22c, consensus 28c

Reports Q4 revenue $168.4M, consensus $166.12M. “2025 was a defining year for Esperion (ESPR). We delivered strong growth in our U.S. cardiovascular franchise, broadened access and adoption among statin intolerant or statin-resistant patients and strengthened the durability of our business with important intellectual property and market access advances,” said Sheldon Koenig, Chief Executive Officer of Esperion. “Importantly, we used this momentum to chart our next chapter with Vision 2040 – a bold plan to build a multiproduct, innovation driven company with continued leadership in cardiometabolic disease and targeted expansion into rare hepatic and renal conditions. Our recently announced agreement to acquire Corstasis Therapeutics represents a compelling and strategically aligned opportunity that accelerates Esperion’s momentum and advances our long-term Vision 2040. Looking ahead, we’re investing against clear catalysts: deeper U.S. market penetration supported by robust payer coverage, advancement of our oral triple combination program designed to rival products on the market or in development and continued geographic expansion with our global partners.”